In addition to SpaceX, AST SpaceMobile will use Blue Origin's unproven New Glenn rocket to launch its next-generation ...

Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...

William Blair analyst Sami Corwin reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) today. The company’s shares closed today at $0.36. Corwin covers the Healthcare sector, focusing on ...

Bluebird (BLUE) delivered earnings and revenue surprises of 18.42% and 42.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Moving iMage Technologies, Inc. , ("MiT"), a leading technology and services company for cinema, Esports, stadiums, arenas and other out-of-home entertainment venues, today announced results for its ...

SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

Radiation Shield Technologies (RST), a leader in advanced personal protection systems, proudly announces that its Demron product line has been awarded the ISO 9001:2015 Certification. This ...

SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Thursday reported a loss of $60.8 million in its third quarter. On a per-share basis, the Somerville, Massachusetts-based ...

On Tuesday, bluebird bio Inc (BLUE) stock saw a decline, ending the day at $0.39 which represents a decrease of $-0.02 or -4.88% from the prior close of $0.41. The stock opened at $0.4 and touched a ...

Analysts estimate that bluebird bio will report an earnings per share (EPS) of $-0.37. Anticipation surrounds bluebird bio's announcement, with investors hoping to hear about both surpassing estimates ...

Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago. These figures are ...

"Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him ...